Hemostatic powder for malignant gastrointestinal tumor bleeding

Malignant gastrointestinal (GI) bleeding poses a significant clinical challenge due to the friable nature of tumor surfaces and abnormal vasculature, leading to high rates of rebleeding and treatment failure.Conventional endoscopic hemostatic methods often prove insufficient in such cases, necessitating alternative strategies.Hemostatic powders, such as TC-325 (Hemospray), have emerged as a viable solution, providing immediate hemostasis by forming a physical barrier at the bleeding site and promoting coagulation.Many studies have demonstrated a high immediate hemostasis rate and reduced rebleeding incidence with hemostatic powders, even in patients where conventional therapies failed.Despite some limitations, such as residual powder interfering with further endoscopic procedures, these agents are generally safe and effective.Further research is needed to establish standardized guidelines and evaluate the long-term outcomes of hemostatic powders in malignant GI bleeding to solidify their role as a standard treatment option.